

GTX INC /DE/  
Form 8-K  
February 02, 2005

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 2, 2005 (February 1, 2005)**

**GTx, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**005-79588**  
(Commission  
File Number)

**62-1715807**  
(I.R.S. Employer  
Identification No.)

**3 N. Dunlap Street  
3<sup>rd</sup> Floor, Van Vleet Building  
Memphis, Tennessee 38163  
(901) 523-9700**

(Address, including zip code, and telephone number,  
including area code, of registrant's principal executive offices)

---

(Former name or former address, if changed since last report)

**TABLE OF CONTENTS**

ITEM 8.01 Other Events.

ITEM 9.01 Financial Statements and Exhibits.

SIGNATURE

PRESS RELEASE

---

**Table of Contents**

ITEM 8.01 Other Events.

On February 1, 2005, GTx, Inc. announced that it has initiated a Phase I clinical trial for ostarine, GTx's second selective androgen receptor modulator (SARM) compound to be tested in clinical trials. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

ITEM 9.01 Financial Statements and Exhibits.

(c) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release issued by GTx, Inc. dated February 1, 2005

---

**Table of Contents**

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GTx, Inc.

Date: February 2, 2005

By: /s/ Henry P. Doggrell  
Name: Henry P. Doggrell  
Title: Vice President, General  
Counsel/Secretary